Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 28 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors				Phase II, Phase I				BMT 0499 Solid NCT00179816
	Monoclonal Antibody IMC-A12 and Doxorubicin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma				Phase II, Phase I				UCCRC-16227A 16227A, 8131, NCT00720174
	Peripheral Stem Cell Transplant and White Blood Cell Transfusions in Treating Patients With Refractory Metastatic Solid Tumors				Phase II				NHLBI-99-H-0064 NCT00003839
	Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Young Patients With Recurrent Sarcoma				Phase II				NCI-02-C-0259H NCT00047372
	Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers				Phase II				UMCC 9626 IRB 1996-195, NCT00141765
	Radiation Therapy to Treat Musculoskeletal Tumors				Phase II				RTSARC NCT00186992
	External Beam Radiation With Intratumoral Injection Of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma				Phase II				MCC-14497 NCT00365872
	A Pilot Study of Tumor Cell Vaccine for High-Risk Solid Tumor Patients Following Stem Cell Transplantation				Phase II				UMCC 2005.050 GCRC ID # 2191, NCT00405327
	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer				Phase II				MSKCC-05122 NCT00445965
	Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor				Phase II				CINJ-3330 NCT00161187


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute